Eiger BioPharmaceuticals (EIGR) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EIGR Hot Sheet
Join SI Premium – FREE
Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q2 EPS of ($0.47), $0.08 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $4.57 million.
For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- PROCEPT BioRobotics Corporation (PRCT) Misses Q3 EPS by 7c
- ITT Inc (ITT) Tops Q3 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
